HSP90 Heat-Shock Proteins, antagonists & inhibitors

All categories
Name
HSP90 Heat-Shock Proteins, antagonists & inhibitors
Accession Number
DBCAT001671
Description

Not Available

Drugs
DrugDrug Description
BIIB021BIIB021 has been investigated for the treatment of Tumors and Lymphoma.
GanetespibGanetespib is under investigation for the treatment of BREAST CANCER, Small Cell Lung Cancer, Acute Myeloid Leukaemia, and Myelodysplastic Syndrome.
IPI-493IPI-493 has been used in trials studying the treatment of Advanced Malignancies.
LuminespibAUY922 has been used in trials studying the treatment of Lymphoma, Breast Cancer, Metastatic Disease, Advanced Solid Tumors, and Hematologic Neoplasms, among others.
OnalespibInvestigated for use/treatment in cancer/tumors (unspecified).
RetaspimycinInvestigated for use/treatment in gastric cancer, lung cancer, and multiple myeloma.
SNX-2112SNX-2112 is a heat shock protein 90 (Hsp90) inhibitor.
TanespimycinInvestigated for use/treatment in leukemia (myeloid) and solid tumors.
XL-888XL888 has been used in trials studying the treatment of Cancer and Melanoma.
Drugs & Drug Targets
DrugTargetType
BIIB021Heat shock protein HSP 90-alphatarget
GanetespibHeat shock protein HSP 90-alphatarget
GanetespibHeat shock protein HSP 90-betatarget
IPI-493Heat shock protein HSP 90-alphatarget
LuminespibHeat shock protein HSP 90-alphatarget
OnalespibHeat shock protein HSP 90-alphatarget
RetaspimycinHeat shock protein HSP 90-alphatarget
RetaspimycinHeat shock protein HSP 90-betatarget
SNX-2112Heat shock protein HSP 90-alphatarget
TanespimycinHeat shock protein HSP 90-alphatarget
TanespimycinHeat shock protein HSP 90-betatarget
TanespimycinAlbumincarrier
XL-888Heat shock protein HSP 90-alphatarget
XL-888Heat shock protein HSP 90-betatarget